Начало › Множествен миелом › Илинойс › Chicago
Клинични проучвания за Множествен миелом в Chicago, IL
22 проучвания за Множествен миелом търсят участници в обекти в и около Chicago (в радиус от около 30 мили). Отворете проучването, за да видите кой може да участва и как да се свържете с екипа.
Официален текст на проучването (английски)
Търсите участници за проучване? Представяме го в началото на тази страница — $99 за 30 дни →
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
Набиране на участнициФаза 1
- University of Chicago Medical Center /ID# 278863, Chicago
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Набиране на участнициФаза 3
- Research Site, Chicago
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Набиране на участнициФаза 1/2
- University of Chicago Medical Center, Chicago
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Набиране на участнициФаза 3
- Rush University System for Health, Chicago
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Набиране на участнициФаза 3
- University Of Illinois Medical Center, Chicago
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Набиране на участнициФаза 4
- Northwestern University, Chicago
- University of Chicago, Chicago
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
Набиране на участнициФаза 2
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Набиране на участнициФаза 2
- Cancer Treatment Centers of America-Chicago, Chicago
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Набиране на участнициФаза 2
- Northwestern Memorial Hospital, Chicago
- University of Chicago Medical Center, Chicago
Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma
Набиране на участнициФаза 2
- University of Illinois at Chicago, Chicago
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Набиране на участнициФаза 3
- Endeavor Health - Swedish Hospital, Chicago
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Набиране на участнициФаза 3
- Advocate Illinois Masonic Medical Center, Chicago
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Набиране на участнициФаза 1/2
- Research Site, Chicago
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Набиране на участнициФаза 3
- Research Site, Chicago
Mosaic Trial for Stem Cell Transplant Recipients
Набиране на участници
- Northwestern University Feinberg School of Medicine, Chicago
Personalized Autologous Transplant for Multiple Myeloma
Набиране на участнициФаза 1
- University Illinois Chicago, Chicago
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Набиране на участнициФаза 3
- University of Chicago, Chicago
- University of Illinois Medical Center at Chicago, Chicago
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Набиране на участнициФаза 1
- University of Chicago, Chicago
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Набиране на участнициФаза 1
- University of Chicago Medical Center, Chicago
Hypofractionation (Radiation) Trial for Multiple Myeloma
Набиране на участнициФаза 1
- The University of Chicago Comprehensive Cancer Center, Chicago
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Набиране на участнициФаза 1/2
- Northwestern, Chicago
Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD
Набиране на участнициФаза 1
- University of Illinois Cancer Center, Chicago
Проучвания за Множествен миелом в други градове
- New York City, NY60 проучвания
- Boston, MA42 проучвания
- Atlanta, GA41 проучвания
- Houston, TX38 проучвания
- Durham, NC37 проучвания
- Nashville, TN32 проучвания
- Denver, CO27 проучвания
- Rochester, MN24 проучвания
- St. Louis, MO24 проучвания
- Columbus, OH24 проучвания
- Baldwin Park, CA23 проучвания
- Seattle, WA22 проучвания
Други проучвания в Chicago
- Рак на белия дроб с недребноклетъчен тип61 проучвания
- Рак на гърдата58 проучвания
- Рак (всички видове)51 проучвания
- Метастатичен рак45 проучвания
- Рак на простатата45 проучвания
- Затлъстяване41 проучвания
- Рак на белия дроб41 проучвания
- Рак на яйчниците36 проучвания
- Инсульт34 проучвания
- Колоректален рак33 проучвания
- Сърдечна недостатъчност31 проучвания
- Наднормено тегло28 проучвания
От ClinicalTrials.gov, данни към 5.10.2026 г.. Всяко проучване има свои критерии за участие; екипът на проучването определя кой може да се включи.